Equities research analysts expect that VIVUS, Inc. (NASDAQ:VVUS) will report earnings of ($0.13) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for VIVUS’s earnings. VIVUS reported earnings of $0.54 per share during the same quarter last year, which would indicate a negative year over year growth rate of 124.1%. The business is expected to report its next quarterly earnings results on Wednesday, March 14th.
On average, analysts expect that VIVUS will report full year earnings of ($0.32) per share for the current fiscal year. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover VIVUS.
VIVUS (NASDAQ:VVUS) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.07. The company had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a return on equity of 344.23% and a net margin of 26.71%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.09) EPS.
A number of hedge funds have recently bought and sold shares of the stock. AJO LP acquired a new position in VIVUS during the 2nd quarter worth approximately $3,329,000. OxFORD Asset Management LLP raised its stake in VIVUS by 14.0% during the 3rd quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock worth $1,040,000 after buying an additional 129,871 shares during the period. Russell Investments Group Ltd. raised its stake in VIVUS by 166.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 246,927 shares during the period. Northern Trust Corp raised its stake in VIVUS by 16.8% during the 2nd quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 39,473 shares during the period. Finally, Macquarie Group Ltd. acquired a new position in VIVUS during the 3rd quarter worth approximately $192,000. 31.30% of the stock is currently owned by institutional investors and hedge funds.
Shares of VIVUS (NASDAQ VVUS) traded up $0.01 during trading hours on Friday, hitting $0.54. The stock had a trading volume of 583,200 shares, compared to its average volume of 593,067. The firm has a market cap of $56.13, a P/E ratio of 1.64 and a beta of 0.80. The company has a debt-to-equity ratio of 643.86, a current ratio of 7.47 and a quick ratio of 7.09. VIVUS has a 12 month low of $0.48 and a 12 month high of $1.38.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/05/0-13-eps-expected-for-vivus-inc-vvus-this-quarter.html.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.